Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
PRESSRELEASE The2016GeorgesMathéPrizerecognizesresearchonthe immunologicaldeterminantsoftheresponsetobreast cancertreatment Paris,October19,2016 The2016GeorgesMathéPrizewaspresentedonOctober10,2016duringtheESMO(European SocietyofMedicalOncology)meetinginCopenhagen.ThePrize,supportingtranslationalresearch ofexcellence,wasestablishedinmemoryofthepioneerofcancerresearchinFrance,Georges Mathé,deceasedin2010.ThePrizewasawardedtoayoungGreekresearcher,DoctorAlexios Matikas,aclinicaloncologistfromtheUniversityHospitalHeraklion,forhisresearchprojecton immunologicaldeterminantsofresponsetotreatmentinbreastcancer.TheFellowshipwillsupport hisresearchinKarolinskaInstitutet(Stockholm,Sweden),intotheimmunologicaldeterminantsof responsetotreatmentinbreastcancer. Createdin2011bytheInstitutduCanceretd'Immunogénétique(ICIG)andsponsoredbythe EuropeanSocietyofMedicalOncology(ESMO),theGeorgesMathéPrizepromotestherapeutic advancesandtranslationalresearchinmedicaloncologyandimmunotherapy,honoringtheearly bench-bedside-benchstudiespioneeredbyProfessorGeorgesMathé.Bestowedbyajurycomposed ofinternationalscientists,the35.000Europrizeisawardedtoanoutstandingyoung physician/scientisttoenablehim/hertopursueacareerintranslationalcancerresearch. Thisyear,theprizewillsupportaresearchprojectaimingatbetterunderstandingtheimmunological determinantsoftreatmentresponseinbreastcancer,atvariousstagesofthedisease(beforesurgery i.e.neo-adjuvant,postsurgeryi.e.adjuvant,metastatic).Tumor-hostinteractionsarerecognizedto beofafundamentalimportanceincancerdevelopment,inparticularthetumor’scapabilitytoinduce animmunosuppressiveenvironmentandevadethehost’simmuneresponsebythemobilizationof variousmechanisms.Theaimoftheprojectwillbetoevaluatetherelevanceofseveral immunologicalmarkers(TumorInfiltratingLymphocytes,TumorAssociatedMacrophages,PD-L1 expression,etc.)inpredictingtheresponsetotreatment,andtodevelopanimmune-relatedgene signaturepredictiveoftheresponse.ThisworkwilltakeplaceattheprestigiousKarolinskaInstitutet underthesupervisionofProfessorTheodorosFoukakis. ProfessorDimitriosMavroudis,HeadoftheMedicalOncologydepartmentatHeraklionUniversity Hospital,wasthrilledbytheawardofthePrizetoAlexiosMatikas:“Alexiosisanoutstandingfellow withadmirableknowledge.Hehasalreadyauthoredmanypublications.Heisalsoafineclinician dedicatedtohispatients.”.DrMatikassharedhisprideandthankfulness:“Ifeelveryluckytobeable tocontinuemyresearchataprestigiouscentersuchastheKarolinksaInstitutetundertheguidance ProfessorFoukakis,andIthanktheESMOandtheGeorgesMathéPrizesponsors”. Byfundingtranslationalresearchintotheimmunologicaldeterminantsoftheresponsetocancer therapy,the2016GeorgesMathéPrizegivespraisetothevisionaryworksofProfessorGeorges Mathé,thepioneerofcancerimmunotherapy,adoptiveimmunotherapywiththefirst-everbone marrowgrafttotreataleukemiapatientandthedevelopmentofthe«Graftvs.Leukemia»concept, andactiveimmunotherapybystimulationofthepatient’simmunesystem,inparticularwithBCG therapy,stillthegoldstandardtodayforthemanagementofearly-stagebladdercancer.Georges Mathéwasconvincedthattheactivationoftheimmunesystemagainstthetumorwastheonlyway toeliminate“thelasttumorcell”,andtherecentsuccessesobtainedbyimmunotherapyin melanomaseemtoprovehimright,morethanfiftyyearsafterhispioneeringworks. TheGeorgesMathéPrize:attheheartofESMO GeorgesMathé,theFrenchpioneerinoncologyandfirsttosuccessfullyachievewithhisteamabone marrowtransplanttotreatleukemia,playedakeyroleinthecreationofESMO,servingasthevery firstPresidentoftheSociety.ESMOpayshimanannualtributebysponsoringtheGeorgesMathé Prize,whichisnowawardedaspartofitsannualcongress.ESMOrecognitiongivesthePrizeamajor visibility. ThePrizeismadepossiblebythefinancialsupportoftheInstitutduCanceretd'Immunogénétique (ICIG)andthepharmaceuticalcompaniesIpsenandtheDebiopharmGroup: TheInstitutduCanceretd'Immunogénétique(ICIG),Villejuif,wasfoundedin1961attheHospital PaulBroussebyProf.GeorgesMathé,whodirectedanddevelopedituntil1990.Itincorporates INSERMresearchlaboratoriesandaclinicalserviceofcancerology.ProfessorMathéservedasthe Institute´sHonoraryPresidentfrom2003-2010. CurrentPresident,Prof.DavidMarchover,discipleofGeorgesMathéandpracticingattheBloodand TumoralDiseaseServiceoftheHospitalPaulBroussethathehadcreated,ishonoredtosupportthe prizeasatributetohisformermentorandfriend. Ipsenisaglobalspecialty-drivenpharmaceuticalgroupwithtotalsalesexceeding€1.4billionin2015. Ipsensellsmorethan20drugsinmorethan115countries,withadirectcommercialpresenceinmore than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeteddebilitatingdiseases.Itsfieldsofexpertisecoveroncology,neurosciencesandendocrinology (adult & pediatric). Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrinetumors.Ipsenalsohasasignificantpresenceinprimarycare.Moreover,theGroup has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technologicalplatforms,peptidesandtoxins,locatedintheheartoftheleadingbiotechnologicaland life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditure totaled close to €193 million. The Group has more than 4,600 employees worldwide. Ipsen’ssharesaretradedonsegmentAofEuronextParis(stockcode:IPN,ISINcode:FR0010259150) 2 and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. IpsenhasimplementedaSponsoredLevelIAmericanDepositaryReceipt(ADR)program,whichtrade ontheover-the-countermarketintheUnitedStatesunderthesymbolIPSEY.Formoreinformationon Ipsen,visitwww.ipsen.com. ThecontributionofIpsentotheGeorgesMathéprizedemonstratesIpsen´ssupporttotherapeutic innovation,andtranslatesinitsprofoundadmirationfortheProf.GeorgesMathé,hisdedicationto patientsandhispioneerworkinoncology.IpsenalsoacknowledgesProf.Mathé´smajorcontribution totheclinicalevaluationoftriptorelin(Décapeptyl®),aleadmoleculeinIpsen´sportfolio,withthe firstpublicationofthephaseIIresultsin1986alongwithProf.A.Schally(Nobellaureate)andDr. Mauvernay,thefounderoftheDebiopharmGroup™. DebiopharmGroup™(Debiopharm)isapharmaceuticalresearchgroupfoundedbyDr.Rolland-Yves Mauverayin1979andbasedinSwitzerland.Thegroupusesitsscientificandclinicalexpertiseto answerunmetmedicalneeds.Debiopharmin-licensespromisingmoleculedrugcandidates. Debiopharmdevelopsitsproductsforglobalregistrationandmaximumcommercialpotentialforoutlicensingtopharmaceuticalpartnersforsalesandmarketing. ThehistoryofDebiopharmandDr.MauverayisintimatelylinkedtothatofProf.GeorgesMathé. Theirlongfriendship,livelyintuition,scientificandintellectualrigorindeedledtothedevelopmentof oxaliplatine.DiscoveredinJapan,thismoleculehasbecome,owingtotheworkofProfMathéandto thetenacityofDr.Mauvernayandtheirteams,anewinternationalstandardinthetreatmentof coloncancerandaleadproductofDebiopharmanditslicensees. Dr.MauvernayandhisgroupareproudtohonorthememoryofGeorgesMathé,oneofthemost importantresearchersofFrenchmedicine,withtherecentawardofthisprizeattheESMOCongress. Moreinformation: YannGaston-Mathé [email protected] +33630079926 3